Overview

Pomaglumetad Effects on Glutamate Biomarkers

Status:
Completed

Trial end date:
2018-05-25

Target enrollment:

Participant gender:

Summary

The study will evaluate the effects of the mGluR2/3 partial agonist LY2140023 (Pomaglumetad Methionil, "POMA") at selected doses on ketamine-stimulated glutamate release in prefrontal cortex as measured by pharmacoBOLD fMRI (also termed resting BOLD fMRI).

Phase:

Phase 1

Details

Lead Sponsor:

New York State Psychiatric Institute

Collaborator:

National Institute of Mental Health (NIMH)